Werewolf Therapeutics’ (HOWL) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a report issued on Wednesday,Weiss Ratings reports.

A number of other brokerages have also recently commented on HOWL. Citigroup restated a “buy” rating on shares of Werewolf Therapeutics in a research note on Monday, August 25th. JMP Securities decreased their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. Finally, Bank of America decreased their target price on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 25th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Werewolf Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Werewolf Therapeutics Stock Performance

Shares of HOWL stock opened at $1.63 on Wednesday. The stock has a market capitalization of $74.54 million, a P/E ratio of -0.99 and a beta of 0.76. The company has a current ratio of 5.30, a quick ratio of 5.30 and a debt-to-equity ratio of 0.60. The firm’s 50 day moving average is $1.51 and its 200 day moving average is $1.23. Werewolf Therapeutics has a 12 month low of $0.60 and a 12 month high of $4.18.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. On average, sell-side analysts anticipate that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

Institutional Trading of Werewolf Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bridgeway Capital Management LLC increased its holdings in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after buying an additional 62,414 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after buying an additional 25,882 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Werewolf Therapeutics in the 2nd quarter worth $409,000. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics in the 2nd quarter worth $48,000. Finally, Marshall Wace LLP bought a new position in shares of Werewolf Therapeutics in the 2nd quarter worth $113,000. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.